Routine CMO departure with replacement search underway, no immediate trading signal. Monitor for the new CMO appointment and any potential impact on clinical trial timelines or pipeline strategy. The separation agreement will be filed with the next 10-Q (quarter ending June 30, 2026) for full terms.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 23 $8.14entry
- T+1 · 5mo ago −1.11%α −1.06% · $8.05
- T+5 · 5mo ago +1.84%α +0.83% · $8.29
- T+20 · 4mo ago −1.47%α −2.63% · $8.02
- T+60 · 2mo ago +0.25%α −3.00% · $8.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arvinas (ARVN) filed an 8-K announcing the departure of Chief Medical Officer Dr. Noah Berkowitz, effective July 3, 2026, with a search for a replacement underway. The departure is described as voluntary to pursue other opportunities, with standard severance including 9 months base salary and accelerated vesting of RSUs through May 9, 2027. This is a routine officer departure for a biotech company, the CMO role is important but not a CEO/CFO-level exit, and the filing lacks any financial data or guidance changes.
Key Facts
- Chief Medical Officer Dr. Noah Berkowitz departing July 3, 2026
- Departure described as voluntary to pursue other opportunities
- Search for replacement CMO has begun
- Severance: 9 months base salary continuation + up to 9 months health coverage
- Accelerated vesting of RSUs that would vest on or before May 9, 2027; all other RSUs forfeited
- Separation agreement includes standard release, confidentiality, and non-disparagement
Financial Impact
No material financial impact disclosed, severance is standard for a C-level officer departure at a ~$500M market cap biotech
Risk Factors
- Potential clinical development disruption if CMO replacement is delayed
- No financial or guidance data in this filing, limited read-through
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-044627 |
| Document: 0001628280-26-044627-index-headers.html | 0001628280-26-044627 |
| Document: 0001628280-26-044627-index.html | 0001628280-26-044627 |
| Document: 0001628280-26-044627.txt | 0001628280-26-044627 |
Track record
21 reports on ARVN
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Viewing Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers